Mechanistic Evaluations on Sorafenib Induced Hypophosphatemia in Patients With Advanced Renal Cell Carcinoma

Trial Profile

Mechanistic Evaluations on Sorafenib Induced Hypophosphatemia in Patients With Advanced Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 19 Jan 2011 Planned end date changed from 1 Jun 2013 to 1 Jan 2014 according to ClinicalTrials.gov.
    • 19 Jan 2011 Status changed from recruiting to discontinued according to ClinicalTrials.gov.
    • 16 Apr 2010 Planned end date changed from 1 Nov 2010 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top